Celadon Pharmaceuticals
Pharmaceutical Manufacturing • 
London, England, United Kingdom • 11-20 Employees
Company overview
| Headquarters | 71-75 Shelton Street, Covent Garden, London, London WC2H 9JQ, GB |
| Phone number | +4411545912 |
| Websites | |
| NAICS | 3254 |
| Keywords | Biotechnology, GMP, Pharmaceuticals, Drug Discovery, Cannabis, Cannabinoids, Drug Manufacturing, Compound Discovery |
| Founded | 2018 |
| Employees | 11-20 |
| Socials |
Key Contacts at Celadon Pharmaceuticals
Don Perrott
Managing Director
Cormac Short
Co-Founder / Cultivation & Technology Manager
Stuart Cornwell
Director Of Business Development
Celadon Pharmaceuticals Email Formats
Celadon Pharmaceuticals uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@celadonpharma.co.uk), used 50% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@celadonpharma.co.uk | 50% |
{first initial} | j@celadonpharma.co.uk | 28.6% |
{first initial}.{last name} | j.doe@celadonpharma.co.uk | 21.4% |
About Celadon Pharmaceuticals
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and supply of breakthrough cannabis-based medicines. Founded in 2018 after cannabis was legalised for medicinal purposes, Celadon was one of the first companies to receive Home Office and MHRA licences to cultivate and produce high-THC medicines. In March 2022, Celadon listed on the AIM market of the London Stock Exchange – a huge milestone in the industry and the first since GW Pharma (who were acquired for $7bn by Jazz in 2021). The Company has a clear mission: to improve quality of life for patients most in need through breakthrough cannabis-based medicines. The primary focus is addressing the 8 million chronic pain sufferers in the UK, who currently have little alternative to opioids. Celadon has a 100,000 sq ft facility in the UK, comprising a large indoor hydroponic cultivation area, proprietary extraction and GMP standard API manufacturing, and an R&D and testing laboratory. It has been estimated by Canaccord that it would cost a new market entrant over £60m and 2-3 years minimum to replicated what Celadon has built in the UK. The Company's subsidiary, LVL Health, owns an MHRA conditionally approved clinical trial using cannabis-based medicines to treat chronic pain in the UK. The initial study is already live and interested patients can learn more here: www.lvlhealth.co.uk Moreover, Celadon has a 20% stake in Kingdom Therapeutics, an early-stage biopharma developed a licenced cannabinoid medicine for children with Autism Spectrum Disorder. This forms part of Celadon’s ‘Breakthrough R&D’ programme, which aims to develop novel IP (molecules, delivery technology) and the future of cannabis-based medicines. Learn more about Celadon here: www.celadonpharma.com
Celadon Pharmaceuticals revenue & valuation
| Annual revenue | $75,000 |
| Revenue per employee | $4,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $240,000 |
| Total funding | $13,800,000 |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Celadon Pharmaceuticals has 10 employees across 7 departments.
Departments
Number of employees
Funding Data
Explore Celadon Pharmaceuticals's funding history, including investment rounds, total capital raised, and key backers.
Celadon Pharmaceuticals Tech Stack
Discover the technologies and tools that power Celadon Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.
Hosting
WordPress themes
WordPress plugins
Page builders
JavaScript libraries
JavaScript libraries
Programming languages
Blogs
Analytics
Font scripts
JavaScript graphics
United States
Canada
Frequently asked questions
4.8
40,000 users
